nodes	percent_of_prediction	percent_of_DWPC	metapath
Levonorgestrel—ESR1—urinary bladder cancer	0.639	1	CbGaD
Levonorgestrel—AR—scrotum—urinary bladder cancer	0.0192	0.209	CbGeAlD
Levonorgestrel—AR—penis—urinary bladder cancer	0.00866	0.0945	CbGeAlD
Levonorgestrel—SRD5A1—prostate gland—urinary bladder cancer	0.00791	0.0864	CbGeAlD
Levonorgestrel—SRD5A1—renal system—urinary bladder cancer	0.00539	0.0589	CbGeAlD
Levonorgestrel—SRD5A1—female reproductive system—urinary bladder cancer	0.00432	0.0471	CbGeAlD
Levonorgestrel—CYP3A4—urine—urinary bladder cancer	0.00316	0.0344	CbGeAlD
Levonorgestrel—SHBG—prostate gland—urinary bladder cancer	0.00288	0.0314	CbGeAlD
Levonorgestrel—PGR—prostate gland—urinary bladder cancer	0.0026	0.0283	CbGeAlD
Levonorgestrel—CYP19A1—prostate gland—urinary bladder cancer	0.00234	0.0255	CbGeAlD
Levonorgestrel—AR—prostate gland—urinary bladder cancer	0.00207	0.0226	CbGeAlD
Levonorgestrel—ESR1—prostate gland—urinary bladder cancer	0.00203	0.0222	CbGeAlD
Levonorgestrel—PGR—epithelium—urinary bladder cancer	0.00191	0.0208	CbGeAlD
Levonorgestrel—PGR—smooth muscle tissue—urinary bladder cancer	0.00184	0.0201	CbGeAlD
Levonorgestrel—AR—seminal vesicle—urinary bladder cancer	0.00175	0.0191	CbGeAlD
Levonorgestrel—SHBG—female reproductive system—urinary bladder cancer	0.00157	0.0172	CbGeAlD
Levonorgestrel—AR—epithelium—urinary bladder cancer	0.00152	0.0166	CbGeAlD
Levonorgestrel—ESR1—epithelium—urinary bladder cancer	0.00149	0.0163	CbGeAlD
Levonorgestrel—AR—smooth muscle tissue—urinary bladder cancer	0.00146	0.016	CbGeAlD
Levonorgestrel—ESR1—smooth muscle tissue—urinary bladder cancer	0.00144	0.0157	CbGeAlD
Levonorgestrel—SHBG—vagina—urinary bladder cancer	0.00142	0.0155	CbGeAlD
Levonorgestrel—PGR—female reproductive system—urinary bladder cancer	0.00142	0.0155	CbGeAlD
Levonorgestrel—AR—renal system—urinary bladder cancer	0.00141	0.0154	CbGeAlD
Levonorgestrel—AR—urethra—urinary bladder cancer	0.00138	0.0151	CbGeAlD
Levonorgestrel—ESR1—renal system—urinary bladder cancer	0.00138	0.0151	CbGeAlD
Levonorgestrel—PGR—vagina—urinary bladder cancer	0.00128	0.014	CbGeAlD
Levonorgestrel—CYP19A1—female reproductive system—urinary bladder cancer	0.00128	0.0139	CbGeAlD
Levonorgestrel—AR—female reproductive system—urinary bladder cancer	0.00113	0.0123	CbGeAlD
Levonorgestrel—ESR1—female reproductive system—urinary bladder cancer	0.00111	0.0121	CbGeAlD
Levonorgestrel—AR—vagina—urinary bladder cancer	0.00102	0.0111	CbGeAlD
Levonorgestrel—Quinestrol—ESR1—urinary bladder cancer	0.00101	0.144	CrCbGaD
Levonorgestrel—ESR1—vagina—urinary bladder cancer	0.001	0.0109	CbGeAlD
Levonorgestrel—Ethynodiol—ESR1—urinary bladder cancer	0.000831	0.118	CrCbGaD
Levonorgestrel—PGR—lymph node—urinary bladder cancer	0.000829	0.00905	CbGeAlD
Levonorgestrel—Allylestrenol—ESR1—urinary bladder cancer	0.000785	0.112	CrCbGaD
Levonorgestrel—CYP3A4—renal system—urinary bladder cancer	0.000772	0.00843	CbGeAlD
Levonorgestrel—Mestranol—ESR1—urinary bladder cancer	0.000765	0.109	CrCbGaD
Levonorgestrel—Desogestrel—ESR1—urinary bladder cancer	0.000756	0.108	CrCbGaD
Levonorgestrel—CYP19A1—lymph node—urinary bladder cancer	0.000746	0.00814	CbGeAlD
Levonorgestrel—Norgestimate—ESR1—urinary bladder cancer	0.000707	0.101	CrCbGaD
Levonorgestrel—AR—lymph node—urinary bladder cancer	0.00066	0.00721	CbGeAlD
Levonorgestrel—ESR1—lymph node—urinary bladder cancer	0.000648	0.00708	CbGeAlD
Levonorgestrel—CYP3A4—female reproductive system—urinary bladder cancer	0.000618	0.00675	CbGeAlD
Levonorgestrel—Etonogestrel—ESR1—urinary bladder cancer	0.000612	0.0871	CrCbGaD
Levonorgestrel—Ethinyl Estradiol—ESR2—urinary bladder cancer	0.000592	0.0843	CrCbGaD
Levonorgestrel—Danazol—ESR1—urinary bladder cancer	0.000394	0.0561	CrCbGaD
Levonorgestrel—Ethinyl Estradiol—ESR1—urinary bladder cancer	0.000365	0.0519	CrCbGaD
Levonorgestrel—Progesterone—ESR1—urinary bladder cancer	0.000204	0.0291	CrCbGaD
Levonorgestrel—Vomiting—Thiotepa—urinary bladder cancer	0.000155	0.000948	CcSEcCtD
Levonorgestrel—Pneumonia—Epirubicin—urinary bladder cancer	0.000155	0.000947	CcSEcCtD
Levonorgestrel—Infestation—Epirubicin—urinary bladder cancer	0.000154	0.000941	CcSEcCtD
Levonorgestrel—Infestation NOS—Epirubicin—urinary bladder cancer	0.000154	0.000941	CcSEcCtD
Levonorgestrel—Rash—Thiotepa—urinary bladder cancer	0.000153	0.00094	CcSEcCtD
Levonorgestrel—Bronchitis—Doxorubicin—urinary bladder cancer	0.000153	0.00094	CcSEcCtD
Levonorgestrel—Dermatitis—Thiotepa—urinary bladder cancer	0.000153	0.000939	CcSEcCtD
Levonorgestrel—Headache—Thiotepa—urinary bladder cancer	0.000152	0.000934	CcSEcCtD
Levonorgestrel—Decreased appetite—Etoposide—urinary bladder cancer	0.000152	0.000931	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000151	0.000925	CcSEcCtD
Levonorgestrel—Body temperature increased—Cisplatin—urinary bladder cancer	0.000151	0.000924	CcSEcCtD
Levonorgestrel—Fatigue—Etoposide—urinary bladder cancer	0.000151	0.000924	CcSEcCtD
Levonorgestrel—Constipation—Etoposide—urinary bladder cancer	0.000149	0.000916	CcSEcCtD
Levonorgestrel—Pain—Etoposide—urinary bladder cancer	0.000149	0.000916	CcSEcCtD
Levonorgestrel—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000149	0.000915	CcSEcCtD
Levonorgestrel—Dysuria—Doxorubicin—urinary bladder cancer	0.000149	0.000914	CcSEcCtD
Levonorgestrel—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000148	0.000909	CcSEcCtD
Levonorgestrel—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000148	0.000908	CcSEcCtD
Levonorgestrel—Haemoglobin—Methotrexate—urinary bladder cancer	0.000148	0.000908	CcSEcCtD
Levonorgestrel—Haemorrhage—Methotrexate—urinary bladder cancer	0.000147	0.000903	CcSEcCtD
Levonorgestrel—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000147	0.000903	CcSEcCtD
Levonorgestrel—Asthenia—Gemcitabine—urinary bladder cancer	0.000147	0.0009	CcSEcCtD
Levonorgestrel—Pharyngitis—Methotrexate—urinary bladder cancer	0.000146	0.000896	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000146	0.000892	CcSEcCtD
Levonorgestrel—Weight increased—Doxorubicin—urinary bladder cancer	0.000145	0.000889	CcSEcCtD
Levonorgestrel—Pruritus—Gemcitabine—urinary bladder cancer	0.000145	0.000887	CcSEcCtD
Levonorgestrel—Nausea—Thiotepa—urinary bladder cancer	0.000145	0.000886	CcSEcCtD
Levonorgestrel—Urethral disorder—Methotrexate—urinary bladder cancer	0.000144	0.000885	CcSEcCtD
Levonorgestrel—Weight decreased—Doxorubicin—urinary bladder cancer	0.000144	0.000884	CcSEcCtD
Levonorgestrel—Sinusitis—Epirubicin—urinary bladder cancer	0.000144	0.000883	CcSEcCtD
Levonorgestrel—Pneumonia—Doxorubicin—urinary bladder cancer	0.000143	0.000876	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000143	0.000876	CcSEcCtD
Levonorgestrel—Pruritus—Fluorouracil—urinary bladder cancer	0.000142	0.000873	CcSEcCtD
Levonorgestrel—Infestation—Doxorubicin—urinary bladder cancer	0.000142	0.000871	CcSEcCtD
Levonorgestrel—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000142	0.000871	CcSEcCtD
Levonorgestrel—Visual impairment—Methotrexate—urinary bladder cancer	0.000142	0.00087	CcSEcCtD
Levonorgestrel—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000141	0.000861	CcSEcCtD
Levonorgestrel—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00014	0.000858	CcSEcCtD
Levonorgestrel—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000139	0.000854	CcSEcCtD
Levonorgestrel—Urticaria—Etoposide—urinary bladder cancer	0.000139	0.000851	CcSEcCtD
Levonorgestrel—Haemoglobin—Epirubicin—urinary bladder cancer	0.000139	0.000849	CcSEcCtD
Levonorgestrel—Rhinitis—Epirubicin—urinary bladder cancer	0.000138	0.000847	CcSEcCtD
Levonorgestrel—Abdominal pain—Etoposide—urinary bladder cancer	0.000138	0.000847	CcSEcCtD
Levonorgestrel—Body temperature increased—Etoposide—urinary bladder cancer	0.000138	0.000847	CcSEcCtD
Levonorgestrel—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000138	0.000847	CcSEcCtD
Levonorgestrel—Haemorrhage—Epirubicin—urinary bladder cancer	0.000138	0.000845	CcSEcCtD
Levonorgestrel—Eye disorder—Methotrexate—urinary bladder cancer	0.000138	0.000844	CcSEcCtD
Levonorgestrel—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000138	0.000844	CcSEcCtD
Levonorgestrel—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000137	0.000841	CcSEcCtD
Levonorgestrel—Asthenia—Cisplatin—urinary bladder cancer	0.000137	0.000839	CcSEcCtD
Levonorgestrel—Pharyngitis—Epirubicin—urinary bladder cancer	0.000137	0.000839	CcSEcCtD
Levonorgestrel—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000137	0.000838	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000136	0.000835	CcSEcCtD
Levonorgestrel—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000136	0.000831	CcSEcCtD
Levonorgestrel—Urethral disorder—Epirubicin—urinary bladder cancer	0.000135	0.000828	CcSEcCtD
Levonorgestrel—Sinusitis—Doxorubicin—urinary bladder cancer	0.000133	0.000817	CcSEcCtD
Levonorgestrel—Immune system disorder—Methotrexate—urinary bladder cancer	0.000133	0.000816	CcSEcCtD
Levonorgestrel—Dizziness—Fluorouracil—urinary bladder cancer	0.000133	0.000816	CcSEcCtD
Levonorgestrel—Visual impairment—Epirubicin—urinary bladder cancer	0.000133	0.000814	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000133	0.000814	CcSEcCtD
Levonorgestrel—Diarrhoea—Cisplatin—urinary bladder cancer	0.000131	0.0008	CcSEcCtD
Levonorgestrel—Erythema multiforme—Epirubicin—urinary bladder cancer	0.00013	0.000799	CcSEcCtD
Levonorgestrel—Alopecia—Methotrexate—urinary bladder cancer	0.00013	0.000798	CcSEcCtD
Levonorgestrel—Vomiting—Gemcitabine—urinary bladder cancer	0.00013	0.000798	CcSEcCtD
Levonorgestrel—Mental disorder—Methotrexate—urinary bladder cancer	0.000129	0.000791	CcSEcCtD
Levonorgestrel—Rash—Gemcitabine—urinary bladder cancer	0.000129	0.000791	CcSEcCtD
Levonorgestrel—Dermatitis—Gemcitabine—urinary bladder cancer	0.000129	0.00079	CcSEcCtD
Levonorgestrel—Eye disorder—Epirubicin—urinary bladder cancer	0.000129	0.00079	CcSEcCtD
Levonorgestrel—Hypersensitivity—Etoposide—urinary bladder cancer	0.000129	0.000789	CcSEcCtD
Levonorgestrel—Erythema—Methotrexate—urinary bladder cancer	0.000128	0.000786	CcSEcCtD
Levonorgestrel—Malnutrition—Methotrexate—urinary bladder cancer	0.000128	0.000786	CcSEcCtD
Levonorgestrel—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000128	0.000786	CcSEcCtD
Levonorgestrel—Headache—Gemcitabine—urinary bladder cancer	0.000128	0.000786	CcSEcCtD
Levonorgestrel—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000128	0.000784	CcSEcCtD
Levonorgestrel—Vomiting—Fluorouracil—urinary bladder cancer	0.000128	0.000784	CcSEcCtD
Levonorgestrel—Rhinitis—Doxorubicin—urinary bladder cancer	0.000128	0.000784	CcSEcCtD
Levonorgestrel—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000128	0.000782	CcSEcCtD
Levonorgestrel—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000127	0.000778	CcSEcCtD
Levonorgestrel—Rash—Fluorouracil—urinary bladder cancer	0.000127	0.000778	CcSEcCtD
Levonorgestrel—Dermatitis—Fluorouracil—urinary bladder cancer	0.000127	0.000777	CcSEcCtD
Levonorgestrel—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000127	0.000776	CcSEcCtD
Levonorgestrel—Headache—Fluorouracil—urinary bladder cancer	0.000126	0.000773	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000126	0.000772	CcSEcCtD
Levonorgestrel—Asthenia—Etoposide—urinary bladder cancer	0.000125	0.000769	CcSEcCtD
Levonorgestrel—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000125	0.000768	CcSEcCtD
Levonorgestrel—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000125	0.000767	CcSEcCtD
Levonorgestrel—Immune system disorder—Epirubicin—urinary bladder cancer	0.000125	0.000763	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000124	0.000762	CcSEcCtD
Levonorgestrel—Back pain—Methotrexate—urinary bladder cancer	0.000124	0.00076	CcSEcCtD
Levonorgestrel—Pruritus—Etoposide—urinary bladder cancer	0.000124	0.000758	CcSEcCtD
Levonorgestrel—Arrhythmia—Epirubicin—urinary bladder cancer	0.000123	0.000755	CcSEcCtD
Levonorgestrel—Visual impairment—Doxorubicin—urinary bladder cancer	0.000123	0.000754	CcSEcCtD
Levonorgestrel—Alopecia—Epirubicin—urinary bladder cancer	0.000122	0.000747	CcSEcCtD
Levonorgestrel—Nausea—Gemcitabine—urinary bladder cancer	0.000122	0.000745	CcSEcCtD
Levonorgestrel—Vomiting—Cisplatin—urinary bladder cancer	0.000121	0.000743	CcSEcCtD
Levonorgestrel—Mental disorder—Epirubicin—urinary bladder cancer	0.000121	0.00074	CcSEcCtD
Levonorgestrel—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000121	0.000739	CcSEcCtD
Levonorgestrel—Rash—Cisplatin—urinary bladder cancer	0.00012	0.000737	CcSEcCtD
Levonorgestrel—Dermatitis—Cisplatin—urinary bladder cancer	0.00012	0.000737	CcSEcCtD
Levonorgestrel—Erythema—Epirubicin—urinary bladder cancer	0.00012	0.000736	CcSEcCtD
Levonorgestrel—Malnutrition—Epirubicin—urinary bladder cancer	0.00012	0.000736	CcSEcCtD
Levonorgestrel—Diarrhoea—Etoposide—urinary bladder cancer	0.00012	0.000733	CcSEcCtD
Levonorgestrel—Nausea—Fluorouracil—urinary bladder cancer	0.00012	0.000733	CcSEcCtD
Levonorgestrel—Eye disorder—Doxorubicin—urinary bladder cancer	0.000119	0.000731	CcSEcCtD
Levonorgestrel—Anaemia—Methotrexate—urinary bladder cancer	0.000119	0.000727	CcSEcCtD
Levonorgestrel—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000118	0.000726	CcSEcCtD
Levonorgestrel—Flatulence—Epirubicin—urinary bladder cancer	0.000118	0.000725	CcSEcCtD
Levonorgestrel—Tension—Epirubicin—urinary bladder cancer	0.000118	0.000722	CcSEcCtD
Levonorgestrel—Nervousness—Epirubicin—urinary bladder cancer	0.000117	0.000715	CcSEcCtD
Levonorgestrel—Back pain—Epirubicin—urinary bladder cancer	0.000116	0.000712	CcSEcCtD
Levonorgestrel—Dizziness—Etoposide—urinary bladder cancer	0.000116	0.000708	CcSEcCtD
Levonorgestrel—Muscle spasms—Epirubicin—urinary bladder cancer	0.000115	0.000707	CcSEcCtD
Levonorgestrel—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000115	0.000706	CcSEcCtD
Levonorgestrel—Vertigo—Methotrexate—urinary bladder cancer	0.000115	0.000706	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000115	0.000705	CcSEcCtD
Levonorgestrel—ESR1—Leptin signaling pathway—SRC—urinary bladder cancer	0.000114	0.00115	CbGpPWpGaD
Levonorgestrel—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000114	0.000699	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—NCOR1—urinary bladder cancer	0.000114	0.00114	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—GSTM1—urinary bladder cancer	0.000114	0.00114	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—ATM—urinary bladder cancer	0.000114	0.00114	CbGpPWpGaD
Levonorgestrel—AR—Androgen receptor signaling pathway—EGFR—urinary bladder cancer	0.000114	0.00114	CbGpPWpGaD
Levonorgestrel—Nausea—Cisplatin—urinary bladder cancer	0.000113	0.000695	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—CDK4—urinary bladder cancer	0.000113	0.00114	CbGpPWpGaD
Levonorgestrel—Alopecia—Doxorubicin—urinary bladder cancer	0.000113	0.000691	CcSEcCtD
Levonorgestrel—Cough—Methotrexate—urinary bladder cancer	0.000112	0.000686	CcSEcCtD
Levonorgestrel—Mental disorder—Doxorubicin—urinary bladder cancer	0.000112	0.000685	CcSEcCtD
Levonorgestrel—Vomiting—Etoposide—urinary bladder cancer	0.000111	0.000681	CcSEcCtD
Levonorgestrel—Malnutrition—Doxorubicin—urinary bladder cancer	0.000111	0.000681	CcSEcCtD
Levonorgestrel—Erythema—Doxorubicin—urinary bladder cancer	0.000111	0.000681	CcSEcCtD
Levonorgestrel—Anaemia—Epirubicin—urinary bladder cancer	0.000111	0.00068	CcSEcCtD
Levonorgestrel—ESR1—Regulation of Telomerase—MYC—urinary bladder cancer	0.000111	0.00112	CbGpPWpGaD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—EP300—urinary bladder cancer	0.000111	0.00111	CbGpPWpGaD
Levonorgestrel—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.00011	0.00111	CbGpPWpGaD
Levonorgestrel—Rash—Etoposide—urinary bladder cancer	0.00011	0.000675	CcSEcCtD
Levonorgestrel—Dermatitis—Etoposide—urinary bladder cancer	0.00011	0.000675	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—RB1—urinary bladder cancer	0.00011	0.00111	CbGpPWpGaD
Levonorgestrel—Headache—Etoposide—urinary bladder cancer	0.00011	0.000671	CcSEcCtD
Levonorgestrel—Flatulence—Doxorubicin—urinary bladder cancer	0.000109	0.000671	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—CDH1—urinary bladder cancer	0.000109	0.0011	CbGpPWpGaD
Levonorgestrel—Myalgia—Methotrexate—urinary bladder cancer	0.000109	0.000669	CcSEcCtD
Levonorgestrel—Chest pain—Methotrexate—urinary bladder cancer	0.000109	0.000669	CcSEcCtD
Levonorgestrel—Tension—Doxorubicin—urinary bladder cancer	0.000109	0.000668	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—GPX1—urinary bladder cancer	0.000109	0.0011	CbGpPWpGaD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000108	0.000665	CcSEcCtD
Levonorgestrel—ESR1—Regulation of Telomerase—EGFR—urinary bladder cancer	0.000108	0.00109	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—MYC—urinary bladder cancer	0.000108	0.00109	CbGpPWpGaD
Levonorgestrel—Discomfort—Methotrexate—urinary bladder cancer	0.000108	0.000661	CcSEcCtD
Levonorgestrel—Nervousness—Doxorubicin—urinary bladder cancer	0.000108	0.000661	CcSEcCtD
Levonorgestrel—Vertigo—Epirubicin—urinary bladder cancer	0.000108	0.000661	CcSEcCtD
Levonorgestrel—Syncope—Epirubicin—urinary bladder cancer	0.000108	0.00066	CcSEcCtD
Levonorgestrel—Back pain—Doxorubicin—urinary bladder cancer	0.000107	0.000658	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—ERCC2—urinary bladder cancer	0.000107	0.00108	CbGpPWpGaD
Levonorgestrel—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000107	0.000654	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	0.000106	0.00107	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	0.000106	0.00107	CbGpPWpGaD
Levonorgestrel—Palpitations—Epirubicin—urinary bladder cancer	0.000106	0.00065	CcSEcCtD
Levonorgestrel—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000106	0.000647	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	0.000105	0.00106	CbGpPWpGaD
Levonorgestrel—Cough—Epirubicin—urinary bladder cancer	0.000105	0.000642	CcSEcCtD
Levonorgestrel—Infection—Methotrexate—urinary bladder cancer	0.000104	0.000637	CcSEcCtD
Levonorgestrel—Nausea—Etoposide—urinary bladder cancer	0.000104	0.000636	CcSEcCtD
Levonorgestrel—Hypertension—Epirubicin—urinary bladder cancer	0.000104	0.000635	CcSEcCtD
Levonorgestrel—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000103	0.000629	CcSEcCtD
Levonorgestrel—Anaemia—Doxorubicin—urinary bladder cancer	0.000103	0.000629	CcSEcCtD
Levonorgestrel—Myalgia—Epirubicin—urinary bladder cancer	0.000102	0.000626	CcSEcCtD
Levonorgestrel—Chest pain—Epirubicin—urinary bladder cancer	0.000102	0.000626	CcSEcCtD
Levonorgestrel—Anxiety—Epirubicin—urinary bladder cancer	0.000102	0.000624	CcSEcCtD
Levonorgestrel—Skin disorder—Methotrexate—urinary bladder cancer	0.000102	0.000623	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000102	0.000622	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000101	0.00062	CcSEcCtD
Levonorgestrel—Discomfort—Epirubicin—urinary bladder cancer	0.000101	0.000619	CcSEcCtD
Levonorgestrel—PGR—Generic Transcription Pathway—NCOR1—urinary bladder cancer	0.000101	0.00101	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—MTHFR—urinary bladder cancer	0.0001	0.00101	CbGpPWpGaD
Levonorgestrel—Vertigo—Doxorubicin—urinary bladder cancer	9.98e-05	0.000612	CcSEcCtD
Levonorgestrel—Anorexia—Methotrexate—urinary bladder cancer	9.98e-05	0.000612	CcSEcCtD
Levonorgestrel—Syncope—Doxorubicin—urinary bladder cancer	9.96e-05	0.00061	CcSEcCtD
Levonorgestrel—AR—Generic Transcription Pathway—ESR2—urinary bladder cancer	9.92e-05	0.000999	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	9.91e-05	0.000998	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—RB1—urinary bladder cancer	9.83e-05	0.00099	CbGpPWpGaD
Levonorgestrel—Palpitations—Doxorubicin—urinary bladder cancer	9.82e-05	0.000602	CcSEcCtD
Levonorgestrel—Oedema—Epirubicin—urinary bladder cancer	9.8e-05	0.0006	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—CDH1—urinary bladder cancer	9.8e-05	0.000986	CbGpPWpGaD
Levonorgestrel—Loss of consciousness—Doxorubicin—urinary bladder cancer	9.76e-05	0.000598	CcSEcCtD
Levonorgestrel—Infection—Epirubicin—urinary bladder cancer	9.74e-05	0.000597	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—EGFR—urinary bladder cancer	9.71e-05	0.000978	CbGpPWpGaD
Levonorgestrel—Cough—Doxorubicin—urinary bladder cancer	9.69e-05	0.000594	CcSEcCtD
Levonorgestrel—Shock—Epirubicin—urinary bladder cancer	9.64e-05	0.000591	CcSEcCtD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—MYC—urinary bladder cancer	9.64e-05	0.000971	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—GSTZ1—urinary bladder cancer	9.62e-05	0.000968	CbGpPWpGaD
Levonorgestrel—Nervous system disorder—Epirubicin—urinary bladder cancer	9.61e-05	0.000589	CcSEcCtD
Levonorgestrel—Hypertension—Doxorubicin—urinary bladder cancer	9.59e-05	0.000588	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	9.54e-05	0.000585	CcSEcCtD
Levonorgestrel—Skin disorder—Epirubicin—urinary bladder cancer	9.52e-05	0.000583	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—CCND1—urinary bladder cancer	9.48e-05	0.000954	CbGpPWpGaD
Levonorgestrel—Hyperhidrosis—Epirubicin—urinary bladder cancer	9.47e-05	0.00058	CcSEcCtD
Levonorgestrel—Insomnia—Methotrexate—urinary bladder cancer	9.47e-05	0.00058	CcSEcCtD
Levonorgestrel—Chest pain—Doxorubicin—urinary bladder cancer	9.46e-05	0.00058	CcSEcCtD
Levonorgestrel—Myalgia—Doxorubicin—urinary bladder cancer	9.46e-05	0.00058	CcSEcCtD
Levonorgestrel—Anxiety—Doxorubicin—urinary bladder cancer	9.43e-05	0.000578	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	9.41e-05	0.000947	CbGpPWpGaD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	9.39e-05	0.000576	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	9.37e-05	0.000943	CbGpPWpGaD
Levonorgestrel—Discomfort—Doxorubicin—urinary bladder cancer	9.34e-05	0.000573	CcSEcCtD
Levonorgestrel—Anorexia—Epirubicin—urinary bladder cancer	9.34e-05	0.000572	CcSEcCtD
Levonorgestrel—Dyspnoea—Methotrexate—urinary bladder cancer	9.34e-05	0.000572	CcSEcCtD
Levonorgestrel—Somnolence—Methotrexate—urinary bladder cancer	9.31e-05	0.00057	CcSEcCtD
Levonorgestrel—Dyspepsia—Methotrexate—urinary bladder cancer	9.22e-05	0.000565	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—KRAS—urinary bladder cancer	9.17e-05	0.000924	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—PTEN—urinary bladder cancer	9.15e-05	0.000921	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—GSTO2—urinary bladder cancer	9.12e-05	0.000918	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—NAT1—urinary bladder cancer	9.12e-05	0.000918	CbGpPWpGaD
Levonorgestrel—Decreased appetite—Methotrexate—urinary bladder cancer	9.1e-05	0.000558	CcSEcCtD
Levonorgestrel—Oedema—Doxorubicin—urinary bladder cancer	9.07e-05	0.000556	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	9.04e-05	0.000554	CcSEcCtD
Levonorgestrel—Fatigue—Methotrexate—urinary bladder cancer	9.03e-05	0.000553	CcSEcCtD
Levonorgestrel—Infection—Doxorubicin—urinary bladder cancer	9.01e-05	0.000552	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	8.97e-05	0.000903	CbGpPWpGaD
Levonorgestrel—Pain—Methotrexate—urinary bladder cancer	8.95e-05	0.000549	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	8.93e-05	0.000547	CcSEcCtD
Levonorgestrel—Shock—Doxorubicin—urinary bladder cancer	8.92e-05	0.000547	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—TP53—urinary bladder cancer	8.9e-05	0.000896	CbGpPWpGaD
Levonorgestrel—Nervous system disorder—Doxorubicin—urinary bladder cancer	8.89e-05	0.000545	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	8.89e-05	0.000895	CbGpPWpGaD
Levonorgestrel—Insomnia—Epirubicin—urinary bladder cancer	8.86e-05	0.000543	CcSEcCtD
Levonorgestrel—Skin disorder—Doxorubicin—urinary bladder cancer	8.81e-05	0.00054	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Doxorubicin—urinary bladder cancer	8.77e-05	0.000537	CcSEcCtD
Levonorgestrel—Dyspnoea—Epirubicin—urinary bladder cancer	8.74e-05	0.000535	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—EP300—urinary bladder cancer	8.73e-05	0.000878	CbGpPWpGaD
Levonorgestrel—Somnolence—Epirubicin—urinary bladder cancer	8.71e-05	0.000534	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	8.69e-05	0.000875	CbGpPWpGaD
Levonorgestrel—Anorexia—Doxorubicin—urinary bladder cancer	8.64e-05	0.00053	CcSEcCtD
Levonorgestrel—Dyspepsia—Epirubicin—urinary bladder cancer	8.63e-05	0.000529	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Methotrexate—urinary bladder cancer	8.56e-05	0.000525	CcSEcCtD
Levonorgestrel—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	8.53e-05	0.000858	CbGpPWpGaD
Levonorgestrel—Decreased appetite—Epirubicin—urinary bladder cancer	8.52e-05	0.000522	CcSEcCtD
Levonorgestrel—AR—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	8.5e-05	0.000856	CbGpPWpGaD
Levonorgestrel—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	8.46e-05	0.000518	CcSEcCtD
Levonorgestrel—Fatigue—Epirubicin—urinary bladder cancer	8.45e-05	0.000518	CcSEcCtD
Levonorgestrel—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	8.41e-05	0.000847	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—HDAC4—urinary bladder cancer	8.41e-05	0.000847	CbGpPWpGaD
Levonorgestrel—Pain—Epirubicin—urinary bladder cancer	8.38e-05	0.000513	CcSEcCtD
Levonorgestrel—Constipation—Epirubicin—urinary bladder cancer	8.38e-05	0.000513	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism—UGT2B7—urinary bladder cancer	8.34e-05	0.00084	CbGpPWpGaD
Levonorgestrel—Urticaria—Methotrexate—urinary bladder cancer	8.32e-05	0.00051	CcSEcCtD
Levonorgestrel—Abdominal pain—Methotrexate—urinary bladder cancer	8.28e-05	0.000507	CcSEcCtD
Levonorgestrel—Body temperature increased—Methotrexate—urinary bladder cancer	8.28e-05	0.000507	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	8.26e-05	0.000506	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—ERBB2—urinary bladder cancer	8.22e-05	0.000828	CbGpPWpGaD
Levonorgestrel—Insomnia—Doxorubicin—urinary bladder cancer	8.2e-05	0.000502	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	8.18e-05	0.000823	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—CCND1—urinary bladder cancer	8.16e-05	0.000821	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—PPARG—urinary bladder cancer	8.14e-05	0.00082	CbGpPWpGaD
Levonorgestrel—Dyspnoea—Doxorubicin—urinary bladder cancer	8.08e-05	0.000495	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	8.08e-05	0.000813	CbGpPWpGaD
Levonorgestrel—Somnolence—Doxorubicin—urinary bladder cancer	8.06e-05	0.000494	CcSEcCtD
Levonorgestrel—ESR1—Leptin signaling pathway—HRAS—urinary bladder cancer	8.05e-05	0.000811	CbGpPWpGaD
Levonorgestrel—Gastrointestinal pain—Epirubicin—urinary bladder cancer	8.01e-05	0.000491	CcSEcCtD
Levonorgestrel—Dyspepsia—Doxorubicin—urinary bladder cancer	7.98e-05	0.000489	CcSEcCtD
Levonorgestrel—PGR—Generic Transcription Pathway—ESR1—urinary bladder cancer	7.9e-05	0.000795	CbGpPWpGaD
Levonorgestrel—Decreased appetite—Doxorubicin—urinary bladder cancer	7.88e-05	0.000483	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—PTEN—urinary bladder cancer	7.87e-05	0.000793	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	7.86e-05	0.000791	CbGpPWpGaD
Levonorgestrel—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	7.83e-05	0.00048	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—CREBBP—urinary bladder cancer	7.82e-05	0.000788	CbGpPWpGaD
Levonorgestrel—Fatigue—Doxorubicin—urinary bladder cancer	7.82e-05	0.000479	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—HRAS—urinary bladder cancer	7.8e-05	0.000785	CbGpPWpGaD
Levonorgestrel—Urticaria—Epirubicin—urinary bladder cancer	7.78e-05	0.000477	CcSEcCtD
Levonorgestrel—Constipation—Doxorubicin—urinary bladder cancer	7.75e-05	0.000475	CcSEcCtD
Levonorgestrel—Pain—Doxorubicin—urinary bladder cancer	7.75e-05	0.000475	CcSEcCtD
Levonorgestrel—Body temperature increased—Epirubicin—urinary bladder cancer	7.75e-05	0.000475	CcSEcCtD
Levonorgestrel—Abdominal pain—Epirubicin—urinary bladder cancer	7.75e-05	0.000475	CcSEcCtD
Levonorgestrel—Hypersensitivity—Methotrexate—urinary bladder cancer	7.71e-05	0.000473	CcSEcCtD
Levonorgestrel—AR—Generic Transcription Pathway—NCOR1—urinary bladder cancer	7.66e-05	0.000771	CbGpPWpGaD
Levonorgestrel—ESR1—Generic Transcription Pathway—ESR2—urinary bladder cancer	7.64e-05	0.000769	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—MYC—urinary bladder cancer	7.6e-05	0.000766	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	7.6e-05	0.000765	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	7.58e-05	0.000763	CbGpPWpGaD
Levonorgestrel—Asthenia—Methotrexate—urinary bladder cancer	7.51e-05	0.00046	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism—CYP4B1—urinary bladder cancer	7.51e-05	0.000756	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—EP300—urinary bladder cancer	7.51e-05	0.000756	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—EGFR—urinary bladder cancer	7.44e-05	0.000749	CbGpPWpGaD
Levonorgestrel—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	7.41e-05	0.000454	CcSEcCtD
Levonorgestrel—Pruritus—Methotrexate—urinary bladder cancer	7.41e-05	0.000454	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—CCND1—urinary bladder cancer	7.3e-05	0.000735	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	7.23e-05	0.000728	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Epirubicin—urinary bladder cancer	7.22e-05	0.000442	CcSEcCtD
Levonorgestrel—PGR—Generic Transcription Pathway—PPARG—urinary bladder cancer	7.21e-05	0.000725	CbGpPWpGaD
Levonorgestrel—Urticaria—Doxorubicin—urinary bladder cancer	7.2e-05	0.000441	CcSEcCtD
Levonorgestrel—PGR—Gene Expression—SMC1A—urinary bladder cancer	7.19e-05	0.000724	CbGpPWpGaD
Levonorgestrel—Abdominal pain—Doxorubicin—urinary bladder cancer	7.17e-05	0.000439	CcSEcCtD
Levonorgestrel—Body temperature increased—Doxorubicin—urinary bladder cancer	7.17e-05	0.000439	CcSEcCtD
Levonorgestrel—Diarrhoea—Methotrexate—urinary bladder cancer	7.16e-05	0.000439	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism—SLC19A1—urinary bladder cancer	7.09e-05	0.000714	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—PTEN—urinary bladder cancer	7.05e-05	0.00071	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—GLI1—urinary bladder cancer	7.05e-05	0.000709	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	7.03e-05	0.000708	CbGpPWpGaD
Levonorgestrel—Asthenia—Epirubicin—urinary bladder cancer	7.03e-05	0.000431	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—CDKN1A—urinary bladder cancer	7.03e-05	0.000707	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—KRAS—urinary bladder cancer	7.03e-05	0.000707	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—PTEN—urinary bladder cancer	7.01e-05	0.000706	CbGpPWpGaD
Levonorgestrel—Pruritus—Epirubicin—urinary bladder cancer	6.93e-05	0.000425	CcSEcCtD
Levonorgestrel—Dizziness—Methotrexate—urinary bladder cancer	6.92e-05	0.000424	CcSEcCtD
Levonorgestrel—PGR—Generic Transcription Pathway—CREBBP—urinary bladder cancer	6.92e-05	0.000697	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PRSS3—urinary bladder cancer	6.91e-05	0.000696	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	6.9e-05	0.000695	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	6.85e-05	0.00069	CbGpPWpGaD
Levonorgestrel—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	6.82e-05	0.000686	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—EP300—urinary bladder cancer	6.72e-05	0.000677	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Epirubicin—urinary bladder cancer	6.7e-05	0.000411	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	6.7e-05	0.000674	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Doxorubicin—urinary bladder cancer	6.68e-05	0.000409	CcSEcCtD
Levonorgestrel—Vomiting—Methotrexate—urinary bladder cancer	6.66e-05	0.000408	CcSEcCtD
Levonorgestrel—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	6.61e-05	0.000666	CbGpPWpGaD
Levonorgestrel—Rash—Methotrexate—urinary bladder cancer	6.6e-05	0.000405	CcSEcCtD
Levonorgestrel—Dermatitis—Methotrexate—urinary bladder cancer	6.6e-05	0.000404	CcSEcCtD
Levonorgestrel—Headache—Methotrexate—urinary bladder cancer	6.56e-05	0.000402	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—MYC—urinary bladder cancer	6.54e-05	0.000659	CbGpPWpGaD
Levonorgestrel—Asthenia—Doxorubicin—urinary bladder cancer	6.51e-05	0.000399	CcSEcCtD
Levonorgestrel—Dizziness—Epirubicin—urinary bladder cancer	6.48e-05	0.000397	CcSEcCtD
Levonorgestrel—Pruritus—Doxorubicin—urinary bladder cancer	6.41e-05	0.000393	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—PTGS2—urinary bladder cancer	6.41e-05	0.000645	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—EGFR—urinary bladder cancer	6.4e-05	0.000644	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	6.3e-05	0.000634	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—ESR2—urinary bladder cancer	6.27e-05	0.000631	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	6.24e-05	0.000629	CbGpPWpGaD
Levonorgestrel—Vomiting—Epirubicin—urinary bladder cancer	6.23e-05	0.000382	CcSEcCtD
Levonorgestrel—Nausea—Methotrexate—urinary bladder cancer	6.22e-05	0.000381	CcSEcCtD
Levonorgestrel—Diarrhoea—Doxorubicin—urinary bladder cancer	6.2e-05	0.00038	CcSEcCtD
Levonorgestrel—Rash—Epirubicin—urinary bladder cancer	6.18e-05	0.000379	CcSEcCtD
Levonorgestrel—Dermatitis—Epirubicin—urinary bladder cancer	6.17e-05	0.000378	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	6.16e-05	0.00062	CbGpPWpGaD
Levonorgestrel—Headache—Epirubicin—urinary bladder cancer	6.14e-05	0.000376	CcSEcCtD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	6.05e-05	0.000609	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—KRAS—urinary bladder cancer	6.05e-05	0.000609	CbGpPWpGaD
Levonorgestrel—AR—Generic Transcription Pathway—ESR1—urinary bladder cancer	6.02e-05	0.000606	CbGpPWpGaD
Levonorgestrel—Dizziness—Doxorubicin—urinary bladder cancer	6e-05	0.000367	CcSEcCtD
Levonorgestrel—ESR1—Generic Transcription Pathway—NCOR1—urinary bladder cancer	5.9e-05	0.000594	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	5.87e-05	0.000591	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—MYC—urinary bladder cancer	5.86e-05	0.00059	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	5.85e-05	0.000589	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	5.84e-05	0.000588	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	5.82e-05	0.000586	CbGpPWpGaD
Levonorgestrel—Nausea—Epirubicin—urinary bladder cancer	5.82e-05	0.000357	CcSEcCtD
Levonorgestrel—Vomiting—Doxorubicin—urinary bladder cancer	5.76e-05	0.000353	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—EGFR—urinary bladder cancer	5.73e-05	0.000577	CbGpPWpGaD
Levonorgestrel—Rash—Doxorubicin—urinary bladder cancer	5.72e-05	0.00035	CcSEcCtD
Levonorgestrel—Dermatitis—Doxorubicin—urinary bladder cancer	5.71e-05	0.00035	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—EGFR—urinary bladder cancer	5.7e-05	0.000574	CbGpPWpGaD
Levonorgestrel—Headache—Doxorubicin—urinary bladder cancer	5.68e-05	0.000348	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—PTEN—urinary bladder cancer	5.59e-05	0.000562	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	5.57e-05	0.000561	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.54e-05	0.000558	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—TYMP—urinary bladder cancer	5.52e-05	0.000556	CbGpPWpGaD
Levonorgestrel—AR—Generic Transcription Pathway—PPARG—urinary bladder cancer	5.49e-05	0.000553	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—SMC1A—urinary bladder cancer	5.48e-05	0.000552	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	5.42e-05	0.000545	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—KRAS—urinary bladder cancer	5.41e-05	0.000545	CbGpPWpGaD
Levonorgestrel—Nausea—Doxorubicin—urinary bladder cancer	5.39e-05	0.00033	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—KRAS—urinary bladder cancer	5.38e-05	0.000542	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	5.37e-05	0.000541	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—EP300—urinary bladder cancer	5.33e-05	0.000536	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.31e-05	0.000534	CbGpPWpGaD
Levonorgestrel—AR—Generic Transcription Pathway—CREBBP—urinary bladder cancer	5.27e-05	0.000531	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	5.17e-05	0.000521	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—NAT2—urinary bladder cancer	5e-05	0.000503	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—HDAC4—urinary bladder cancer	4.94e-05	0.000497	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	4.85e-05	0.000489	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—NCOR1—urinary bladder cancer	4.84e-05	0.000487	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—RBX1—urinary bladder cancer	4.83e-05	0.000486	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	4.81e-05	0.000484	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—ESR2—urinary bladder cancer	4.78e-05	0.000481	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	4.75e-05	0.000478	CbGpPWpGaD
Levonorgestrel—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	4.58e-05	0.000461	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—HRAS—urinary bladder cancer	4.58e-05	0.000461	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—ERCC2—urinary bladder cancer	4.55e-05	0.000458	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TSC1—urinary bladder cancer	4.54e-05	0.000457	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	4.52e-05	0.000455	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	4.52e-05	0.000455	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	4.48e-05	0.000452	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—JAG1—urinary bladder cancer	4.32e-05	0.000435	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—RRM2—urinary bladder cancer	4.31e-05	0.000434	CbGpPWpGaD
Levonorgestrel—ESR1—Generic Transcription Pathway—PPARG—urinary bladder cancer	4.23e-05	0.000426	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—SMC1A—urinary bladder cancer	4.22e-05	0.000425	CbGpPWpGaD
Levonorgestrel—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	4.21e-05	0.000424	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	4.15e-05	0.000418	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—GLI1—urinary bladder cancer	4.14e-05	0.000416	CbGpPWpGaD
Levonorgestrel—PGR—Generic Transcription Pathway—MYC—urinary bladder cancer	4.11e-05	0.000414	CbGpPWpGaD
Levonorgestrel—ESR1—Generic Transcription Pathway—CREBBP—urinary bladder cancer	4.06e-05	0.000409	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—ENO2—urinary bladder cancer	3.99e-05	0.000402	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—HPGDS—urinary bladder cancer	3.99e-05	0.000402	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.99e-05	0.000401	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.97e-05	0.0004	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—GSTT1—urinary bladder cancer	3.87e-05	0.00039	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.81e-05	0.000384	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—ESR1—urinary bladder cancer	3.8e-05	0.000383	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—NCOR1—urinary bladder cancer	3.69e-05	0.000371	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—ESR2—urinary bladder cancer	3.68e-05	0.00037	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—S100B—urinary bladder cancer	3.5e-05	0.000352	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—PPARG—urinary bladder cancer	3.47e-05	0.000349	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—ERCC2—urinary bladder cancer	3.47e-05	0.000349	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—CREBBP—urinary bladder cancer	3.33e-05	0.000336	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—NQO1—urinary bladder cancer	3.22e-05	0.000324	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—NCOR1—urinary bladder cancer	3.15e-05	0.000317	CbGpPWpGaD
Levonorgestrel—AR—Generic Transcription Pathway—MYC—urinary bladder cancer	3.13e-05	0.000315	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.12e-05	0.000314	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—ESR1—urinary bladder cancer	2.9e-05	0.000292	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—NCOR1—urinary bladder cancer	2.84e-05	0.000286	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—RBX1—urinary bladder cancer	2.83e-05	0.000285	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.81e-05	0.000283	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TERT—urinary bladder cancer	2.77e-05	0.000279	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.72e-05	0.000274	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—GSTP1—urinary bladder cancer	2.69e-05	0.00027	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—ERCC2—urinary bladder cancer	2.67e-05	0.000269	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TSC1—urinary bladder cancer	2.67e-05	0.000268	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.66e-05	0.000268	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.66e-05	0.000268	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—PPARG—urinary bladder cancer	2.64e-05	0.000266	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.6e-05	0.000262	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—FGFR3—urinary bladder cancer	2.55e-05	0.000256	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—CREBBP—urinary bladder cancer	2.54e-05	0.000256	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—JAG1—urinary bladder cancer	2.54e-05	0.000255	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—TYMS—urinary bladder cancer	2.5e-05	0.000251	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—ESR1—urinary bladder cancer	2.47e-05	0.000249	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—NCOR1—urinary bladder cancer	2.47e-05	0.000248	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—GSTM1—urinary bladder cancer	2.47e-05	0.000248	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.43e-05	0.000245	CbGpPWpGaD
Levonorgestrel—ESR1—Generic Transcription Pathway—MYC—urinary bladder cancer	2.41e-05	0.000243	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—GPX1—urinary bladder cancer	2.36e-05	0.000238	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—ERCC2—urinary bladder cancer	2.32e-05	0.000234	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	2.19e-05	0.000221	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—MTHFR—urinary bladder cancer	2.18e-05	0.00022	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CREBBP—urinary bladder cancer	2.17e-05	0.000218	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IGF1—urinary bladder cancer	2.14e-05	0.000215	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.07e-05	0.000208	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—S100B—urinary bladder cancer	2.05e-05	0.000207	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—PPARG—urinary bladder cancer	2.04e-05	0.000205	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.02e-05	0.000203	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—MYC—urinary bladder cancer	1.98e-05	0.000199	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—RHOA—urinary bladder cancer	1.96e-05	0.000197	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—CREBBP—urinary bladder cancer	1.96e-05	0.000197	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NCOR1—urinary bladder cancer	1.85e-05	0.000186	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—ERBB2—urinary bladder cancer	1.81e-05	0.000183	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PPARG—urinary bladder cancer	1.77e-05	0.000178	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CXCL8—urinary bladder cancer	1.72e-05	0.000173	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—CREBBP—urinary bladder cancer	1.7e-05	0.000171	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IL2—urinary bladder cancer	1.64e-05	0.000166	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TERT—urinary bladder cancer	1.63e-05	0.000164	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.61e-05	0.000162	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CCND1—urinary bladder cancer	1.6e-05	0.000161	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MMP9—urinary bladder cancer	1.56e-05	0.000157	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CDKN1A—urinary bladder cancer	1.55e-05	0.000156	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PTEN—urinary bladder cancer	1.55e-05	0.000156	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—MYC—urinary bladder cancer	1.51e-05	0.000152	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—FGFR3—urinary bladder cancer	1.49e-05	0.00015	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—EP300—urinary bladder cancer	1.48e-05	0.000149	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.46e-05	0.000147	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—SRC—urinary bladder cancer	1.44e-05	0.000144	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PTGS2—urinary bladder cancer	1.39e-05	0.00014	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MYC—urinary bladder cancer	1.29e-05	0.000129	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CREBBP—urinary bladder cancer	1.27e-05	0.000128	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.26e-05	0.000127	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—EGFR—urinary bladder cancer	1.26e-05	0.000127	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IGF1—urinary bladder cancer	1.26e-05	0.000126	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PTEN—urinary bladder cancer	1.21e-05	0.000122	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—KRAS—urinary bladder cancer	1.19e-05	0.00012	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.17e-05	0.000117	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.17e-05	0.000117	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—MYC—urinary bladder cancer	1.16e-05	0.000117	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—EP300—urinary bladder cancer	1.16e-05	0.000116	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—RHOA—urinary bladder cancer	1.15e-05	0.000116	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.13e-05	0.000114	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—ERBB2—urinary bladder cancer	1.07e-05	0.000107	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TP53—urinary bladder cancer	1.06e-05	0.000106	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CXCL8—urinary bladder cancer	1.01e-05	0.000102	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—HRAS—urinary bladder cancer	1.01e-05	0.000102	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IL2—urinary bladder cancer	9.65e-06	9.72e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CCND1—urinary bladder cancer	9.41e-06	9.47e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NQO1—urinary bladder cancer	9.4e-06	9.46e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MMP9—urinary bladder cancer	9.14e-06	9.2e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CDKN1A—urinary bladder cancer	9.1e-06	9.16e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PTEN—urinary bladder cancer	9.08e-06	9.14e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—EP300—urinary bladder cancer	8.66e-06	8.72e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—SRC—urinary bladder cancer	8.42e-06	8.48e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	7.84e-06	7.89e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MYC—urinary bladder cancer	7.55e-06	7.6e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—EGFR—urinary bladder cancer	7.38e-06	7.43e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—TYMS—urinary bladder cancer	7.29e-06	7.33e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	7.2e-06	7.25e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	7.2e-06	7.25e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—KRAS—urinary bladder cancer	6.97e-06	7.02e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GPX1—urinary bladder cancer	6.9e-06	6.94e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	6.77e-06	6.82e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	6.36e-06	6.41e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TP53—urinary bladder cancer	6.2e-06	6.24e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—HRAS—urinary bladder cancer	5.93e-06	5.97e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PPARG—urinary bladder cancer	5.16e-06	5.2e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.96e-06	4.99e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	4.06e-06	4.09e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.54e-06	3.56e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.38e-06	3.4e-05	CbGpPWpGaD
